PF-08046033 / Pfizer - LARVOL DELTA

PF-08046033 (GPS): A novel first in class auristatin S antibody-drug conjugate for treatment of GPNMB-expressing solid tumors (AACR 2026) - "A previous GPNMB-targeting ADC, Glembatumumab vedotin (GV), comprised of a monoclonal antibody (mAb) conjugated to the microtubule disrupting agent monomethyl auristatin E (MMAE), showed early signs of efficacy. Notably, in NHP toxicology studies, GPS was tolerated at 15 mg/kg, which is five-fold higher than GV. Altogether, these data support the evaluation of PF-08046033 (GPS) in a first-in-human phase 1 clinical trial for the treatment of multiple solid tumors."

ADC • First-in-human • Esophageal Squamous Cell Carcinoma • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • BRCA • GPNMB • SECTM1

Phase 1 Study of PF-08046033 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=250 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • IO biomarker • Cutaneous Melanoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Skin Cancer • Solid Tumor • PD-L1

Phase 1 Study of PF-08046033 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=250 | Not yet recruiting | Sponsor: Pfizer

IO biomarker • New P1 trial • Cutaneous Melanoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Skin Cancer • Solid Tumor • PD-L1